Details of the Drug Combinations

General Information of This Drug (ID: DM2OZ3G)

Drug Name
Ixabepilone   DM2OZ3G
Synonyms Azaepothilone B; BMS-247550; Ixempra (TN)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Breast carcinoma N.A. Approved [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

459 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Ixabepilone DCJP8K0 10-hydroxycamptothecin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
ABIRATERONE + Ixabepilone DCHKAU7 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
ABIRATERONE + Ixabepilone DC4ZEC1 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
ABIRATERONE + Ixabepilone DCF80QB ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [4]
ABIRATERONE + Ixabepilone DCXXM9C ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
ABIRATERONE + Ixabepilone DCQ96LH ABIRATERONE Carcinoma (Cell Line: MCF7) [5]
ABIRATERONE + Ixabepilone DC4WZA1 ABIRATERONE Colon carcinoma (Cell Line: KM12) [5]
ABIRATERONE + Ixabepilone DC9FWLL ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [5]
ABIRATERONE + Ixabepilone DC43MZS ABIRATERONE Adenocarcinoma (Cell Line: HCC-2998) [3]
ABIRATERONE + Ixabepilone DCOKC2R ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
ABIRATERONE + Ixabepilone DCFMMAO ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [3]
ABIRATERONE + Ixabepilone DCM5ZTM ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [3]
ABIRATERONE + Ixabepilone DC4MYSJ ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Amonafide + Ixabepilone DCN2UHD Amonafide Adenocarcinoma (Cell Line: DU-145) [4]
Amonafide + Ixabepilone DCI84K8 Amonafide Adenocarcinoma (Cell Line: A549) [4]
Amonafide + Ixabepilone DC9MQQL Amonafide Adenocarcinoma (Cell Line: HCT-15) [4]
Amonafide + Ixabepilone DCZ7ZGQ Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Amonafide + Ixabepilone DCK9R9T Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Amonafide + Ixabepilone DCCLHA8 Amonafide Amelanotic melanoma (Cell Line: M14) [4]
Amonafide + Ixabepilone DC8V8OK Amonafide Astrocytoma (Cell Line: U251) [4]
Amonafide + Ixabepilone DCJ7ZSV Amonafide Astrocytoma (Cell Line: SNB-19) [4]
Amonafide + Ixabepilone DC6LHDX Amonafide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Amonafide + Ixabepilone DCZRZ1C Amonafide Glioma (Cell Line: SF-295) [4]
Amonafide + Ixabepilone DCY13QG Amonafide Malignant melanoma (Cell Line: UACC62) [4]
Amonafide + Ixabepilone DCT1CR6 Amonafide Malignant melanoma (Cell Line: LOX IMVI) [4]
Amonafide + Ixabepilone DCFEH7X Amonafide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Anastrozole + Ixabepilone DCOXPS5 Anastrozole Adenocarcinoma (Cell Line: HT29) [4]
Anastrozole + Ixabepilone DCUPFA5 Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Anastrozole + Ixabepilone DCBQPJ2 Anastrozole Amelanotic melanoma (Cell Line: M14) [4]
Anastrozole + Ixabepilone DCNIHXY Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Anastrozole + Ixabepilone DC1EAFZ Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Anastrozole + Ixabepilone DCFHHEZ Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Anastrozole + Ixabepilone DC1WG6J Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Anastrozole + Ixabepilone DC9364J Anastrozole Malignant melanoma (Cell Line: UACC62) [4]
Anastrozole + Ixabepilone DCEMP73 Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [4]
Anastrozole + Ixabepilone DC4DR81 Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Anastrozole + Ixabepilone DCY0MOJ Anastrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Anastrozole + Ixabepilone DCYGQ3V Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [5]
Arfolitixorin + Ixabepilone DC9KF45 Arfolitixorin Adenocarcinoma (Cell Line: HCT-15) [3]
Azacitidine + Ixabepilone DCHWGZH Azacitidine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Azacitidine + Ixabepilone DC0WR5E Azacitidine Astrocytoma (Cell Line: SNB-19) [4]
Azacitidine + Ixabepilone DCHPJSA Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Azacitidine + Ixabepilone DCD91GV Azacitidine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Azacitidine + Ixabepilone DC7SSOR Azacitidine Malignant melanoma (Cell Line: UACC62) [4]
Azacitidine + Ixabepilone DC61H92 Azacitidine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Azacitidine + Ixabepilone DC2AO8O Azacitidine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Bendamustine hydrochloride + Ixabepilone DC68AZF Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Bendamustine hydrochloride + Ixabepilone DCN8MWL Bendamustine hydrochloride Glioma (Cell Line: SF-295) [4]
Bendamustine hydrochloride + Ixabepilone DC10RXO Bendamustine hydrochloride Adenocarcinoma (Cell Line: DU-145) [3]
Bendamustine hydrochloride + Ixabepilone DCE24JF Bendamustine hydrochloride Adenocarcinoma (Cell Line: SW-620) [3]
Bendamustine hydrochloride + Ixabepilone DCTKDUR Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Bendamustine hydrochloride + Ixabepilone DCGN4N1 Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [3]
BIO-300 + Ixabepilone DCQ87D0 BIO-300 Astrocytoma (Cell Line: SNB-19) [4]
BIO-300 + Ixabepilone DCSNOJB BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
BIO-300 + Ixabepilone DC5GNW3 BIO-300 Glioma (Cell Line: SF-268) [4]
BIO-300 + Ixabepilone DC18Y85 BIO-300 Renal cell carcinoma (Cell Line: SN12C) [4]
BIO-300 + Ixabepilone DCDN1VU BIO-300 Invasive ductal carcinoma (Cell Line: BT-549) [5]
BIO-300 + Ixabepilone DCL1PJS BIO-300 Adenocarcinoma (Cell Line: NCIH23) [3]
BIO-300 + Ixabepilone DCGSYTI BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [3]
BIO-300 + Ixabepilone DCE8X2P BIO-300 Amelanotic melanoma (Cell Line: M14) [3]
BIO-300 + Ixabepilone DC77HVF BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [3]
BIO-300 + Ixabepilone DCRAYZY BIO-300 Malignant melanoma (Cell Line: UACC62) [3]
BIO-300 + Ixabepilone DCRSA7X BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
BIO-300 + Ixabepilone DCKN3I1 BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Bleomycin + Ixabepilone DCR4FH3 Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Bleomycin + Ixabepilone DCI0KMB Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Bleomycin + Ixabepilone DCE9HY5 Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Bleomycin + Ixabepilone DCTUSD6 Bleomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Bleomycin + Ixabepilone DCSOI37 Bleomycin Adenocarcinoma (Cell Line: A549) [3]
Bleomycin + Ixabepilone DCINPWK Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Cabazitaxel + Ixabepilone DC5O2TG Cabazitaxel Adenocarcinoma (Cell Line: A549) [4]
Cabazitaxel + Ixabepilone DCNWZTX Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Cabazitaxel + Ixabepilone DCFGI2B Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [4]
Cabazitaxel + Ixabepilone DC3JPVI Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Cabazitaxel + Ixabepilone DC1W8QH Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [4]
Cabazitaxel + Ixabepilone DCKEMOW Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Cabazitaxel + Ixabepilone DC6AC0I Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Cabazitaxel + Ixabepilone DCX0JNZ Cabazitaxel Astrocytoma (Cell Line: SNB-19) [4]
Cabazitaxel + Ixabepilone DCMEB6E Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [4]
Cabazitaxel + Ixabepilone DCYMFL1 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Cabazitaxel + Ixabepilone DC1TR7U Cabazitaxel Glioma (Cell Line: SF-268) [4]
Cabazitaxel + Ixabepilone DCN2XVL Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Cabazitaxel + Ixabepilone DCCUZWU Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Cabazitaxel + Ixabepilone DCYID9A Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [4]
Cabazitaxel + Ixabepilone DCMVSV5 Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Cabazitaxel + Ixabepilone DC173SU Cabazitaxel Malignant melanoma (Cell Line: LOX IMVI) [4]
Cabazitaxel + Ixabepilone DCL99S5 Cabazitaxel Melanoma (Cell Line: MALME-3M) [4]
Cabazitaxel + Ixabepilone DCC5NPP Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Cabazitaxel + Ixabepilone DCZZBOF Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Cabazitaxel + Ixabepilone DCWFABA Cabazitaxel Colon carcinoma (Cell Line: KM12) [5]
Cabazitaxel + Ixabepilone DC53UXQ Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [5]
Chlorambucil + Ixabepilone DCFTAS2 Chlorambucil Colon adenocarcinoma (Cell Line: COLO 205) [5]
Crizotinib + Ixabepilone DCQJCZ2 Crizotinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Crizotinib + Ixabepilone DCO4DKK Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Crizotinib + Ixabepilone DC4Y55I Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Crizotinib + Ixabepilone DCES29K Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Crizotinib + Ixabepilone DCO5XHI Crizotinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Crizotinib + Ixabepilone DCGEGDT Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Crizotinib + Ixabepilone DCK8KWX Crizotinib Carcinoma (Cell Line: MCF7) [5]
Crizotinib + Ixabepilone DCU7UID Crizotinib Colon carcinoma (Cell Line: KM12) [5]
Crizotinib + Ixabepilone DCRQ15A Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + Ixabepilone DC6VRXG Cyclophosphamide Adenocarcinoma (Cell Line: A549) [4]
Cyclophosphamide + Ixabepilone DC0D39J Cyclophosphamide Adenocarcinoma (Cell Line: HCT116) [4]
Cyclophosphamide + Ixabepilone DCBIZ4I Cyclophosphamide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Cyclophosphamide + Ixabepilone DCYC2XV Cyclophosphamide Melanoma (Cell Line: MALME-3M) [4]
Cyclophosphamide + Ixabepilone DC02HYN Cyclophosphamide Colon adenocarcinoma (Cell Line: COLO 205) [5]
Cyclophosphamide + Ixabepilone DC5HF60 Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Dacarbazine + Ixabepilone DCRNWF6 Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dacarbazine + Ixabepilone DCRWB6Q Dacarbazine Amelanotic melanoma (Cell Line: M14) [4]
Dacarbazine + Ixabepilone DC5DPAN Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Dacarbazine + Ixabepilone DCX8M0X Dacarbazine Malignant melanoma (Cell Line: LOX IMVI) [4]
Dacarbazine + Ixabepilone DCPTAK1 Dacarbazine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Dactinomycin + Ixabepilone DCQXK3Y Dactinomycin Adenocarcinoma (Cell Line: HT29) [3]
Dactinomycin + Ixabepilone DCJHAX5 Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Dactinomycin + Ixabepilone DCJRZHG Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Dactinomycin + Ixabepilone DCO1EFG Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Dactinomycin + Ixabepilone DC3WY3W Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dactinomycin + Ixabepilone DCRV1QB Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Dactinomycin + Ixabepilone DCWHJ0C Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Dasatinib + Ixabepilone DCZ9PFL Dasatinib Adenocarcinoma (Cell Line: A549) [4]
Dasatinib + Ixabepilone DCUET4E Dasatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dasatinib + Ixabepilone DCA7FZO Dasatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Dasatinib + Ixabepilone DC6X78B Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
DFN-15 + Ixabepilone DCUPWWL DFN-15 Adenocarcinoma (Cell Line: HCT116) [3]
Digitoxin + Ixabepilone DCO5B2W Digitoxin Adenocarcinoma (Cell Line: HCT-15) [4]
Digitoxin + Ixabepilone DCFE3OX Digitoxin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Docetaxel + Ixabepilone DCZ252C Docetaxel Adenocarcinoma (Cell Line: HT29) [4]
Docetaxel + Ixabepilone DC1IBG9 Docetaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Docetaxel + Ixabepilone DCRV3W5 Docetaxel Glioma (Cell Line: SF-268) [4]
Docetaxel + Ixabepilone DCCKBY9 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Docetaxel + Ixabepilone DCM968D Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Docetaxel + Ixabepilone DC3CPW0 Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Ixabepilone DC3SEXX Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Epirubicin + Ixabepilone DC3UL71 Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [3]
ER819762 + Ixabepilone DCMUA15 ER819762 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
ER819762 + Ixabepilone DC831RC ER819762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
ER819762 + Ixabepilone DCW868A ER819762 Adenocarcinoma (Cell Line: DU-145) [3]
Estramustine + Ixabepilone DCPJA4U Estramustine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Estramustine + Ixabepilone DCITS02 Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
FORMESTANE + Ixabepilone DCPVV9S FORMESTANE Adenocarcinoma (Cell Line: HCC-2998) [4]
Fulvestrant + Ixabepilone DCWU6S5 Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Fulvestrant + Ixabepilone DCWLGP7 Fulvestrant Chronic myelogenous leukemia (Cell Line: K-562) [4]
Fulvestrant + Ixabepilone DCS2YAP Fulvestrant Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Fulvestrant + Ixabepilone DCJE447 Fulvestrant Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Fulvestrant + Ixabepilone DCWZUNA Fulvestrant Colon adenocarcinoma (Cell Line: COLO 205) [5]
Gefitinib + Ixabepilone DCHQ3UZ Gefitinib Adenocarcinoma (Cell Line: DU-145) [4]
Gefitinib + Ixabepilone DCKYLTZ Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Gefitinib + Ixabepilone DCNLLI2 Gefitinib Amelanotic melanoma (Cell Line: M14) [4]
Gefitinib + Ixabepilone DCVZ4AG Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Gefitinib + Ixabepilone DCAUBNV Gefitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Gefitinib + Ixabepilone DC60EXW Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Gefitinib + Ixabepilone DC4BGZX Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Gefitinib + Ixabepilone DC242M6 Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Hepzato + Ixabepilone DC4J4BN Hepzato Clear cell renal cell carcinoma (Cell Line: A498) [4]
Hepzato + Ixabepilone DC14AD1 Hepzato Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Hepzato + Ixabepilone DC7XQDF Hepzato Adenocarcinoma (Cell Line: HCC-2998) [3]
Idarubicin + Ixabepilone DCZCV6I Idarubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Ifosfamide + Ixabepilone DCO1CGS Ifosfamide Melanoma (Cell Line: MALME-3M) [4]
Ifosfamide + Ixabepilone DCMVQFY Ifosfamide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Imatinib + Ixabepilone DCW8SFD Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Imatinib + Ixabepilone DCYUYEK Imatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Imatinib + Ixabepilone DC2HUE5 Imatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Imatinib + Ixabepilone DC9SLFG Imatinib Lung adenocarcinoma (Cell Line: EKVX) [4]
Imatinib + Ixabepilone DCBWQ7V Imatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Indazole derivative 5 + Ixabepilone DCBNCOE Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Indazole derivative 5 + Ixabepilone DCHH0H3 Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Indazole derivative 5 + Ixabepilone DCMPH81 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Indazole derivative 5 + Ixabepilone DCKIFQ5 Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Indazole derivative 5 + Ixabepilone DCL16MC Indazole derivative 5 Carcinoma (Cell Line: MCF7) [5]
Indazole derivative 5 + Ixabepilone DCUNQTL Indazole derivative 5 Lung adenocarcinoma (Cell Line: EKVX) [3]
Indazole derivative 5 + Ixabepilone DC67G6T Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Indazole derivative 5 + Ixabepilone DCLTWKM Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Ixabepilone + Panobinostat DCQFZCZ Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ixabepilone + Arsenic trioxide DC8Y3AC Arsenic trioxide Clear cell renal cell carcinoma (Cell Line: A498) [4]
Ixabepilone + Marizomib DC4IW81 Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ixabepilone + Bortezomib DCVJXOD Bortezomib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ixabepilone + Bortezomib DCZQ3A6 Bortezomib Astrocytoma (Cell Line: SNB-19) [4]
Ixabepilone + Bortezomib DC0UU96 Bortezomib Glioma (Cell Line: SF-268) [4]
Ixabepilone + Bortezomib DCBAAII Bortezomib Renal cell carcinoma (Cell Line: SN12C) [4]
Ixabepilone + Bortezomib DC21UB4 Bortezomib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Ixabepilone + Bortezomib DCP73XA Bortezomib Carcinoma (Cell Line: RXF 393) [5]
Ixabepilone + Arsenic trioxide DC1W1RD Arsenic trioxide Adenocarcinoma (Cell Line: HCT116) [3]
Ixabepilone + Bortezomib DCOHFI6 Bortezomib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Ixabepilone + Bortezomib DC9WBWH Bortezomib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Ixabepilone + Bortezomib DCLU7NJ Bortezomib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Ixabepilone + Bortezomib DCGAFT0 Bortezomib Melanoma (Cell Line: SK-MEL-2) [3]
Ixabepilone + Bortezomib DCB3MC6 Bortezomib Prostate carcinoma (Cell Line: PC-3) [3]
Ixabepilone + Cisplatin DCOJPIZ Cisplatin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
JNK-IN-8 + Ixabepilone DCKKQOJ JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
JNK-IN-8 + Ixabepilone DCBS631 JNK-IN-8 Glioma (Cell Line: SF-295) [4]
JNK-IN-8 + Ixabepilone DC98LV4 JNK-IN-8 Adenocarcinoma (Cell Line: DU-145) [3]
JNK-IN-8 + Ixabepilone DCKEDYN JNK-IN-8 Adenocarcinoma (Cell Line: OVCAR3) [3]
JNK-IN-8 + Ixabepilone DCR7JUH JNK-IN-8 Adenocarcinoma (Cell Line: HCC-2998) [3]
JNK-IN-8 + Ixabepilone DCKLK19 JNK-IN-8 Adenocarcinoma (Cell Line: HCT-15) [3]
JNK-IN-8 + Ixabepilone DC7RSZI JNK-IN-8 Lung adenocarcinoma (Cell Line: HOP-62) [3]
JNK-IN-8 + Ixabepilone DCE5FH5 JNK-IN-8 Malignant melanoma (Cell Line: LOX IMVI) [3]
JNK-IN-8 + Ixabepilone DC3MQ4J JNK-IN-8 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Lapatinib + Ixabepilone DCQAZJN Lapatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Lapatinib + Ixabepilone DCXH0P2 Lapatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Lapatinib + Ixabepilone DCGWFE4 Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Lenalidomide + Ixabepilone DC5I7SL Lenalidomide Adenocarcinoma (Cell Line: HCT-15) [3]
Lenalidomide + Ixabepilone DCJHW0J Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Letrozole + Ixabepilone DC48QDY Letrozole Melanoma (Cell Line: SK-MEL-2) [4]
LIAROZOLE + Ixabepilone DCZ025P LIAROZOLE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
LIAROZOLE + Ixabepilone DCHAVZB LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
LIAROZOLE + Ixabepilone DC8S7BW LIAROZOLE Lung adenocarcinoma (Cell Line: HOP-62) [3]
Mechlorethamine + Ixabepilone DC50GUQ Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Methotrexate + Ixabepilone DCL8TCC Methotrexate Glioma (Cell Line: SF-539) [4]
Mitomycin + Ixabepilone DC49DYI Mitomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Mitomycin + Ixabepilone DCW9A22 Mitomycin Astrocytoma (Cell Line: U251) [4]
Nilotinib + Ixabepilone DCS2TFJ Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Pentostatin + Ixabepilone DCXPZI3 Pentostatin Adenocarcinoma (Cell Line: SW-620) [4]
Pentostatin + Ixabepilone DCTVMVH Pentostatin Adenocarcinoma (Cell Line: HCT116) [4]
Pentostatin + Ixabepilone DC20SL7 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Pentostatin + Ixabepilone DCYE7WZ Pentostatin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Picoplatin + Ixabepilone DCOKANG Picoplatin Adenocarcinoma (Cell Line: NCIH23) [3]
Picoplatin + Ixabepilone DC32TH9 Picoplatin Adenocarcinoma (Cell Line: HCT-15) [3]
Picoplatin + Ixabepilone DCD6H56 Picoplatin Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Picoplatin + Ixabepilone DCGKM2M Picoplatin Prostate carcinoma (Cell Line: PC-3) [3]
Plicamycin + Ixabepilone DCMRQDO Plicamycin Glioma (Cell Line: SF-539) [4]
Plicamycin + Ixabepilone DCVKP7D Plicamycin Glioma (Cell Line: SF-268) [4]
Plicamycin + Ixabepilone DCNF2QI Plicamycin Renal cell carcinoma (Cell Line: UO-31) [4]
Plicamycin + Ixabepilone DCN9R62 Plicamycin Renal cell carcinoma (Cell Line: SN12C) [4]
Plicamycin + Ixabepilone DC257F1 Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Plicamycin + Ixabepilone DC06B03 Plicamycin Colon carcinoma (Cell Line: KM12) [5]
Plicamycin + Ixabepilone DCG4HAM Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Ixabepilone DCNX3GE Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Plicamycin + Ixabepilone DCEVVEF Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Ixabepilone DCRM5LV Plicamycin Adenocarcinoma (Cell Line: DU-145) [3]
Plicamycin + Ixabepilone DCSYXRO Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [3]
Plicamycin + Ixabepilone DCMB17E Plicamycin Adenocarcinoma (Cell Line: NCIH23) [3]
Plicamycin + Ixabepilone DCLCRGC Plicamycin Adenocarcinoma (Cell Line: A549) [3]
Plicamycin + Ixabepilone DC220KC Plicamycin Adenocarcinoma (Cell Line: HCT116) [3]
Plicamycin + Ixabepilone DC4EGJ1 Plicamycin Adenocarcinoma (Cell Line: SW-620) [3]
Plicamycin + Ixabepilone DCI1QY8 Plicamycin Adenocarcinoma (Cell Line: HT29) [3]
Plicamycin + Ixabepilone DCZVGX2 Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Plicamycin + Ixabepilone DCJH2AX Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Plicamycin + Ixabepilone DCDGJQL Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Plicamycin + Ixabepilone DC56Y86 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Plicamycin + Ixabepilone DC42R4B Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Plicamycin + Ixabepilone DCZ6HFA Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Plicamycin + Ixabepilone DCQZJWA Plicamycin Malignant melanoma (Cell Line: UACC62) [3]
Plicamycin + Ixabepilone DCIP6J5 Plicamycin Melanoma (Cell Line: UACC-257) [3]
Plicamycin + Ixabepilone DCC50IM Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Plicamycin + Ixabepilone DCDCH3X Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
PMID28460551-Compound-2 + Ixabepilone DC1Y9WY PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
PMID28460551-Compound-2 + Ixabepilone DCCVYNW PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [5]
PMID28460551-Compound-2 + Ixabepilone DCL1UOM PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: COLO 205) [5]
PMID28460551-Compound-2 + Ixabepilone DCVDW7A PMID28460551-Compound-2 Colon carcinoma (Cell Line: KM12) [5]
PMID28460551-Compound-2 + Ixabepilone DCALFPL PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [5]
PMID28460551-Compound-2 + Ixabepilone DCTZDSQ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DU-145) [3]
PMID28460551-Compound-2 + Ixabepilone DC78IDL PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [3]
PMID28460551-Compound-2 + Ixabepilone DCS89N5 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [3]
PMID28460551-Compound-2 + Ixabepilone DCILY0B PMID28460551-Compound-2 Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
PMID28460551-Compound-2 + Ixabepilone DCQ6SB3 PMID28460551-Compound-2 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
PMID28460551-Compound-2 + Ixabepilone DCXS5HM PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
PMID28460551-Compound-2 + Ixabepilone DC3PKTQ PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [3]
PMID28460551-Compound-2 + Ixabepilone DCOCAUT PMID28460551-Compound-2 Melanoma (Cell Line: SK-MEL-2) [3]
PMID28460551-Compound-2 + Ixabepilone DC9VINL PMID28460551-Compound-2 Melanoma (Cell Line: UACC-257) [3]
Pomalidomide + Ixabepilone DC90BIP Pomalidomide Adenocarcinoma (Cell Line: HT29) [4]
Pralatrexate + Ixabepilone DC7M4UU Pralatrexate Astrocytoma (Cell Line: U251) [4]
Pralatrexate + Ixabepilone DCGGPPW Pralatrexate Chronic myelogenous leukemia (Cell Line: K-562) [4]
Pralatrexate + Ixabepilone DC45MNH Pralatrexate Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Pralatrexate + Ixabepilone DC31ALK Pralatrexate Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Pralatrexate + Ixabepilone DCAK4HZ Pralatrexate Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Pralatrexate + Ixabepilone DC83LZ8 Pralatrexate Carcinoma (Cell Line: RXF 393) [5]
Pralatrexate + Ixabepilone DC1Z9I7 Pralatrexate Colon carcinoma (Cell Line: KM12) [5]
Pralatrexate + Ixabepilone DC1X7FW Pralatrexate Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Pralatrexate + Ixabepilone DCNFCJQ Pralatrexate Invasive ductal carcinoma (Cell Line: T-47D) [5]
Pralatrexate + Ixabepilone DCH8WVU Pralatrexate Invasive ductal carcinoma (Cell Line: BT-549) [5]
Pralatrexate + Ixabepilone DCG52FM Pralatrexate Adenocarcinoma (Cell Line: DU-145) [3]
Pralatrexate + Ixabepilone DC76LTM Pralatrexate Adenocarcinoma (Cell Line: OVCAR3) [3]
Pralatrexate + Ixabepilone DC94TVP Pralatrexate Adenocarcinoma (Cell Line: A549) [3]
Pralatrexate + Ixabepilone DCMMZCL Pralatrexate Adenocarcinoma (Cell Line: HT29) [3]
Pralatrexate + Ixabepilone DC3XOXY Pralatrexate Adenocarcinoma (Cell Line: HCC-2998) [3]
Pralatrexate + Ixabepilone DC8T9SJ Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [3]
Pralatrexate + Ixabepilone DCPX9M9 Pralatrexate Adenocarcinoma (Cell Line: SW-620) [3]
Pralatrexate + Ixabepilone DC6CWSM Pralatrexate Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Pralatrexate + Ixabepilone DCAT01W Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Pralatrexate + Ixabepilone DCHO683 Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Pralatrexate + Ixabepilone DCY5CN8 Pralatrexate Lung adenocarcinoma (Cell Line: HOP-62) [3]
Pralatrexate + Ixabepilone DCZWMBC Pralatrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Pralatrexate + Ixabepilone DC5MIYT Pralatrexate Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Pralatrexate + Ixabepilone DC1IODN Pralatrexate Malignant melanoma (Cell Line: UACC62) [3]
Pralatrexate + Ixabepilone DCVDIQ1 Pralatrexate Melanoma (Cell Line: UACC-257) [3]
Pralatrexate + Ixabepilone DCL995A Pralatrexate Melanoma (Cell Line: SK-MEL-2) [3]
Pralatrexate + Ixabepilone DCZIF49 Pralatrexate Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Pralatrexate + Ixabepilone DC41ZAT Pralatrexate Prostate carcinoma (Cell Line: PC-3) [3]
Raloxifene + Ixabepilone DCHLCJD Raloxifene Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Raloxifene + Ixabepilone DC95LEU Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Raloxifene + Ixabepilone DC4PX4D Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Raloxifene + Ixabepilone DC1D8QY Raloxifene Adenocarcinoma (Cell Line: DU-145) [3]
Raloxifene + Ixabepilone DCLCF5E Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Raloxifene + Ixabepilone DCKR99R Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Romidepsin + Ixabepilone DCQUK1N Romidepsin Astrocytoma (Cell Line: U251) [4]
Romidepsin + Ixabepilone DCH3HCG Romidepsin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Romidepsin + Ixabepilone DCG53HW Romidepsin Carcinoma (Cell Line: RXF 393) [5]
Romidepsin + Ixabepilone DC1MGSD Romidepsin Colon carcinoma (Cell Line: KM12) [5]
Romidepsin + Ixabepilone DCQZMME Romidepsin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Romidepsin + Ixabepilone DCIDIBH Romidepsin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Romidepsin + Ixabepilone DCOJFQS Romidepsin Adenocarcinoma (Cell Line: DU-145) [3]
Romidepsin + Ixabepilone DCT2AR8 Romidepsin Adenocarcinoma (Cell Line: OVCAR3) [3]
Romidepsin + Ixabepilone DC8TS4S Romidepsin Adenocarcinoma (Cell Line: A549) [3]
Romidepsin + Ixabepilone DC9Z3ZF Romidepsin Adenocarcinoma (Cell Line: HCT-15) [3]
Romidepsin + Ixabepilone DCBGZ1O Romidepsin Adenocarcinoma (Cell Line: HCT116) [3]
Romidepsin + Ixabepilone DC5FZ27 Romidepsin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Romidepsin + Ixabepilone DCLVQSJ Romidepsin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Romidepsin + Ixabepilone DCO56PM Romidepsin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Romidepsin + Ixabepilone DCC7GYI Romidepsin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Romidepsin + Ixabepilone DCOK3PZ Romidepsin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Romidepsin + Ixabepilone DCU4CU5 Romidepsin Malignant melanoma (Cell Line: UACC62) [3]
Romidepsin + Ixabepilone DC9EU4V Romidepsin Melanoma (Cell Line: UACC-257) [3]
Romidepsin + Ixabepilone DCHW0SQ Romidepsin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Ruxolitinib + Ixabepilone DCQDB17 Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Ruxolitinib + Ixabepilone DCQ2429 Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Ruxolitinib + Ixabepilone DC46XTQ Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Ruxolitinib + Ixabepilone DC25Q0Y Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Ruxolitinib + Ixabepilone DCY0EDM Ruxolitinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Ruxolitinib + Ixabepilone DC76S0G Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Ruxolitinib + Ixabepilone DCVKFD3 Ruxolitinib Carcinoma (Cell Line: MCF7) [5]
Ruxolitinib + Ixabepilone DCX17DK Ruxolitinib Colon carcinoma (Cell Line: KM12) [5]
Ruxolitinib + Ixabepilone DC2O64X Ruxolitinib Adenocarcinoma (Cell Line: SW-620) [3]
Ruxolitinib + Ixabepilone DCDKK7Z Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Ruxolitinib + Ixabepilone DCXK5DS Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Ruxolitinib + Ixabepilone DC3Z354 Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Ruxolitinib + Ixabepilone DC8PMKK Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
SCH 727965 + Ixabepilone DCNR31D SCH 727965 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
SCH 727965 + Ixabepilone DCUNFBK SCH 727965 Chronic myelogenous leukemia (Cell Line: K-562) [4]
SCH 727965 + Ixabepilone DCIR0UF SCH 727965 Invasive ductal carcinoma (Cell Line: BT-549) [5]
SCH 727965 + Ixabepilone DCIS5WG SCH 727965 Adenocarcinoma (Cell Line: DU-145) [3]
SCH 727965 + Ixabepilone DC9M9GB SCH 727965 Adenocarcinoma (Cell Line: SW-620) [3]
SCH 727965 + Ixabepilone DC949DQ SCH 727965 Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
SCH 727965 + Ixabepilone DCFLRLC SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
SCH 727965 + Ixabepilone DCXWXCM SCH 727965 Malignant melanoma (Cell Line: UACC62) [3]
SCH 727965 + Ixabepilone DCPSNVX SCH 727965 Melanoma (Cell Line: SK-MEL-2) [3]
Sirolimus + Ixabepilone DC61FG7 Sirolimus Glioma (Cell Line: SF-268) [4]
Sirolimus + Ixabepilone DCW9IWU Sirolimus Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Sirolimus + Ixabepilone DC4Z39Y Sirolimus Colon carcinoma (Cell Line: KM12) [5]
Sirolimus + Ixabepilone DCRQ515 Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sirolimus + Ixabepilone DC3NB7A Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Sirolimus + Ixabepilone DCPAOTX Sirolimus Malignant melanoma (Cell Line: UACC62) [3]
Sorafenib + Ixabepilone DCG4VRS Sorafenib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Sorafenib + Ixabepilone DCYC52A Sorafenib Carcinoma (Cell Line: MCF7) [5]
Sorafenib + Ixabepilone DCECKT2 Sorafenib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Sorafenib + Ixabepilone DC94IV1 Sorafenib Colon carcinoma (Cell Line: KM12) [5]
Sorafenib + Ixabepilone DC4I4PL Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
SY-1425 + Ixabepilone DCKB2OG SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
SY-1425 + Ixabepilone DC1R8H9 SY-1425 Adenocarcinoma (Cell Line: HCC-2998) [3]
SY-1425 + Ixabepilone DC6BDLS SY-1425 Adenocarcinoma (Cell Line: HCT116) [3]
SY-1425 + Ixabepilone DCS7K5U SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
SY-1425 + Ixabepilone DCBE2A9 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
SY-1425 + Ixabepilone DC3ZNQG SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
SY-1425 + Ixabepilone DCDX2SK SY-1425 Melanoma (Cell Line: MALME-3M) [3]
Taxol + Ixabepilone DCEQJX2 Taxol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Taxol + Ixabepilone DC797B8 Taxol Astrocytoma (Cell Line: SNB-19) [4]
Taxol + Ixabepilone DCFS6SN Taxol Chronic myelogenous leukemia (Cell Line: K-562) [4]
Taxol + Ixabepilone DCQ3I8Q Taxol Glioma (Cell Line: SF-539) [4]
Taxol + Ixabepilone DC8QC3O Taxol Renal cell carcinoma (Cell Line: SN12C) [4]
Taxol + Ixabepilone DC87P8P Taxol Colon adenocarcinoma (Cell Line: COLO 205) [5]
Taxol + Ixabepilone DCA2G0N Taxol Colon carcinoma (Cell Line: KM12) [5]
Taxol + Ixabepilone DC5U5XG Taxol Invasive ductal carcinoma (Cell Line: T-47D) [5]
Taxol + Ixabepilone DCGXSWR Taxol Adenocarcinoma (Cell Line: DU-145) [3]
Taxol + Ixabepilone DCY6EV0 Taxol Adenocarcinoma (Cell Line: A549) [3]
Taxol + Ixabepilone DCR3171 Taxol Adenocarcinoma (Cell Line: SW-620) [3]
Taxol + Ixabepilone DC3HERI Taxol Adenocarcinoma (Cell Line: HT29) [3]
Taxol + Ixabepilone DC30OND Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Taxol + Ixabepilone DCSWR1P Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Taxol + Ixabepilone DCXL5MF Taxol Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Taxol + Ixabepilone DC5AT0U Taxol Malignant melanoma (Cell Line: UACC62) [3]
Taxol + Ixabepilone DC33HGQ Taxol Prostate carcinoma (Cell Line: PC-3) [3]
Thioguanine + Ixabepilone DCMA3BL Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Thioguanine + Ixabepilone DCZ8G0S Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Thioguanine + Ixabepilone DCCVCU9 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Thioguanine + Ixabepilone DCSVITX Thioguanine Astrocytoma (Cell Line: SNB-19) [4]
Thioguanine + Ixabepilone DCEVC0W Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Thioguanine + Ixabepilone DC9R2P9 Thioguanine Glioblastoma (Cell Line: SNB-75) [4]
Thioguanine + Ixabepilone DCIN5VQ Thioguanine Glioma (Cell Line: SF-295) [4]
Thioguanine + Ixabepilone DCI7XAD Thioguanine Carcinoma (Cell Line: MCF7) [5]
Thioguanine + Ixabepilone DC4M121 Thioguanine Adenocarcinoma (Cell Line: DU-145) [3]
Thioguanine + Ixabepilone DCPKXJW Thioguanine Adenocarcinoma (Cell Line: HCT-15) [3]
Thioguanine + Ixabepilone DC8FSX8 Thioguanine Amelanotic melanoma (Cell Line: M14) [3]
Thioguanine + Ixabepilone DCVQT42 Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Thioguanine + Ixabepilone DC9K1TN Thioguanine Malignant melanoma (Cell Line: UACC62) [3]
Topotecan + Ixabepilone DCJY3VL Topotecan Carcinoma (Cell Line: MCF7) [5]
Topotecan + Ixabepilone DCDZ77D Topotecan Adenocarcinoma (Cell Line: A549) [3]
Topotecan + Ixabepilone DC0QH2K Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Topotecan + Ixabepilone DCHI5BJ Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Topotecan + Ixabepilone DCZLZNS Topotecan Amelanotic melanoma (Cell Line: M14) [3]
Topotecan + Ixabepilone DCPLZSI Topotecan Astrocytoma (Cell Line: SNB-19) [3]
Topotecan + Ixabepilone DC32JCJ Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Topotecan + Ixabepilone DCU2CLV Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Topotecan + Ixabepilone DCF8YDG Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Topotecan + Ixabepilone DCCDE0U Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Topotecan + Ixabepilone DCFBBKQ Topotecan Melanoma (Cell Line: MALME-3M) [3]
Topotecan + Ixabepilone DC6XIC2 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Topotecan + Ixabepilone DC7WY5T Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Topotecan + Ixabepilone DCROCG9 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Topotecan + Ixabepilone DCJ614K Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Topotecan + Ixabepilone DCC017O Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Topotecan + Ixabepilone DC2IQIG Topotecan Prostate carcinoma (Cell Line: PC-3) [3]
Triapine + Ixabepilone DC3EDCE Triapine Colon carcinoma (Cell Line: KM12) [5]
Trifluridine + Ixabepilone DCXR9I8 Trifluridine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Trifluridine + Ixabepilone DCSZHBA Trifluridine Astrocytoma (Cell Line: SNB-19) [4]
Trifluridine + Ixabepilone DC8EUKD Trifluridine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Trifluridine + Ixabepilone DC85KBL Trifluridine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Trifluridine + Ixabepilone DCE232J Trifluridine Glioblastoma (Cell Line: SNB-75) [4]
Trifluridine + Ixabepilone DC16VQP Trifluridine Glioma (Cell Line: SF-295) [4]
Trifluridine + Ixabepilone DC5W2G7 Trifluridine Carcinoma (Cell Line: MCF7) [5]
Trifluridine + Ixabepilone DCWXHKQ Trifluridine Adenocarcinoma (Cell Line: DU-145) [3]
Trifluridine + Ixabepilone DC52AQ9 Trifluridine Adenocarcinoma (Cell Line: OVCAR3) [3]
Trifluridine + Ixabepilone DCPBLNE Trifluridine Adenocarcinoma (Cell Line: HCC-2998) [3]
Trifluridine + Ixabepilone DCM2DXB Trifluridine Adenocarcinoma (Cell Line: HCT116) [3]
Trifluridine + Ixabepilone DCKYIN9 Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Trifluridine + Ixabepilone DCAXZPN Trifluridine Malignant melanoma (Cell Line: LOX IMVI) [3]
Trifluridine + Ixabepilone DCH44JL Trifluridine Melanoma (Cell Line: MALME-3M) [3]
Trifluridine + Ixabepilone DC6P14Y Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Trifluridine + Ixabepilone DCJ5Y1O Trifluridine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Trifluridine + Ixabepilone DCX07QI Trifluridine Prostate carcinoma (Cell Line: PC-3) [3]
Uracil mustard + Ixabepilone DCE8RHF Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [4]
Uracil mustard + Ixabepilone DCMCOYR Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Uracil mustard + Ixabepilone DC8KJHD Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Uracil mustard + Ixabepilone DCJG6SL Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [3]
Valrubicin + Ixabepilone DCKPWPI Valrubicin Astrocytoma (Cell Line: U251) [4]
Valrubicin + Ixabepilone DCZDB1U Valrubicin Glioma (Cell Line: SF-295) [4]
Valrubicin + Ixabepilone DCVQ11N Valrubicin Colon carcinoma (Cell Line: KM12) [5]
Valrubicin + Ixabepilone DC5K6H1 Valrubicin Adenocarcinoma (Cell Line: NCIH23) [3]
Valrubicin + Ixabepilone DCLN0OZ Valrubicin Adenocarcinoma (Cell Line: HCC-2998) [3]
Valrubicin + Ixabepilone DCO7P2R Valrubicin Adenocarcinoma (Cell Line: HT29) [3]
Vandetanib + Ixabepilone DC6P6VQ Vandetanib Adenocarcinoma (Cell Line: HCC-2998) [3]
Vandetanib + Ixabepilone DCB8BLP Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Vandetanib + Ixabepilone DCHP04P Vandetanib Lung adenocarcinoma (Cell Line: EKVX) [3]
Vandetanib + Ixabepilone DCY6JUY Vandetanib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Vemurafenib + Ixabepilone DCL6636 Vemurafenib Carcinoma (Cell Line: MCF7) [5]
Vemurafenib + Ixabepilone DC8KDOL Vemurafenib Adenocarcinoma (Cell Line: HT29) [3]
Vemurafenib + Ixabepilone DC6ORC6 Vemurafenib Amelanotic melanoma (Cell Line: M14) [3]
Vemurafenib + Ixabepilone DCQH8UY Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Vemurafenib + Ixabepilone DCAWUXX Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Vemurafenib + Ixabepilone DCYIIA1 Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Vemurafenib + Ixabepilone DCZ1CO3 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Vemurafenib + Ixabepilone DC6ANF6 Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Vemurafenib + Ixabepilone DCBUPXP Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Vemurafenib + Ixabepilone DC0CSKK Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [3]
Vemurafenib + Ixabepilone DCDAF15 Vemurafenib Melanoma (Cell Line: UACC-257) [3]
Vemurafenib + Ixabepilone DC970SC Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Vincristine + Ixabepilone DCPCT0Z Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vincristine + Ixabepilone DCLLJVH Vincristine Glioma (Cell Line: SF-268) [4]
Vincristine + Ixabepilone DCF6WH8 Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vinflunine + Ixabepilone DCRBR5Z Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Vinflunine + Ixabepilone DCGD7HX Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Vismodegib + Ixabepilone DCKY9GL Vismodegib Carcinoma (Cell Line: MCF7) [5]
Vismodegib + Ixabepilone DC69ALR Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vismodegib + Ixabepilone DCRZUAK Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [3]
Vismodegib + Ixabepilone DC1QECS Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Vismodegib + Ixabepilone DCK6KHR Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Vismodegib + Ixabepilone DCYNBTR Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [3]
Vismodegib + Ixabepilone DC2NUO9 Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Vismodegib + Ixabepilone DC4E8EW Vismodegib Malignant melanoma (Cell Line: UACC62) [3]
Vismodegib + Ixabepilone DC541O3 Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Vismodegib + Ixabepilone DCPQ841 Vismodegib Prostate carcinoma (Cell Line: PC-3) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 459 DrugCom(s)
12 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ixabepilone + Pazopanib DC17RJ7 Pazopanib Breast Cancer [6]
Ixabepilone + Capecitabine DC5T6JM Capecitabine Breast Cancer [7]
Ixabepilone + Pemetrexed DC9XGP2 Pemetrexed Advanced Solid Tumors [8]
Ixabepilone + Epirubicin DCBITL6 Epirubicin Metastatic Breast Cancer [9]
Ixabepilone + Carboplatin DCCWIPB Carboplatin Unspecified Adult Solid Tumor, Protocol Specific [10]
Ixabepilone + Dasatinib DCDJY6C Dasatinib Metastatic Breast Cancer [11]
Ixabepilone + Rifampicin DCL21D9 Rifampicin Advanced Solid Tumors [12]
Ixabepilone + Carboplatin DCLBSIK Carboplatin HER2-positive Breast Cancer [13]
Ixabepilone + Cyclophosphamide DCSR81T Cyclophosphamide Breast Cancer [14]
Ixabepilone + Dasatinib DCU2K0O Dasatinib Solid Tumor [15]
Ixabepilone + Hydroxychloroquine DCZWQCY Hydroxychloroquine Breast Cancer [16]
Ixabepilone + Capecitabine DCY6JTI Capecitabine Breast Cancer [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
2 Ixabepilone FDA Label
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 ClinicalTrials.gov (NCT01012362) Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
7 ClinicalTrials.gov (NCT00568022) A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
8 ClinicalTrials.gov (NCT01170871) Ixabepilone and Pemetrexed/Solid Tumors
9 ClinicalTrials.gov (NCT00322374) Phase I Combination w/ Epirubicin
10 ClinicalTrials.gov (NCT00028561) BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
11 ClinicalTrials.gov (NCT00924352) Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
12 ClinicalTrials.gov (NCT00207090) Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
13 ClinicalTrials.gov (NCT00077376) Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
14 ClinicalTrials.gov (NCT00866905) Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
15 ClinicalTrials.gov (NCT00717704) Solid Tumors Using Ixabepilone and Dasatinib
16 ClinicalTrials.gov (NCT00765765) Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
17 ClinicalTrials.gov (NCT01349088) Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer